Molecular Templates, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters
  • Pipeline
    • Overview
    • MT-3724
    • MT-5111
    • TAK-169
  • Clinical Trials
    • Overview
    • MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-3724 for Relapsed or Refractory DLBCL Active, not recruiting
    • MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-5111 in HER2-positive Solid Tumors Recruiting
    • TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference

Aug 14, 2017 8:00am EDT

Molecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements

Aug 02, 2017 8:30am EDT

Molecular Templates Announces Presentations Featuring Engineered Toxin Bodies at the 2017 American Association for Cancer Research (AACR) Annual Meeting

Mar 30, 2017 4:01pm EDT

Molecular Templates to Present Clinical and Preclinical Data for MT-3724 and Next Generation Engineered Toxin Bodies (ETBs) at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Apr 06, 2016 8:30am EDT

Molecular Templates Collaborates with the MD Anderson Cancer Center on Research of MT-3724 in Chemo-Resistant Aggressive B-Cell Lymphomas

Oct 08, 2015 8:30am EDT

Molecular Templates Presents Preclinical Data on De-Immunized Engineered Toxin Bodies (ETB) with Novel Immuno-Oncology Capabilities at the 2015 AACR Annual Meeting

Apr 16, 2015 8:00am EDT

Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma

Mar 05, 2015 8:00am EST

Molecular Templates Presents Preclinical Data on CD38-Targeted Engineered Toxin Body (ETB) at the American Association for Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries to Novel Therapies

Sep 24, 2014 8:30am EDT

Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizing Immunotoxin MT-3724

Sep 08, 2014 9:00am EDT

Molecular Templates Presents Preclinical Data on Engineered Toxin Bodies (ETBs) at the AACR Annual Meeting

Apr 18, 2014 8:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    Next
    © 2021 Molecular Templates, Inc. All Rights Reserved.
    Twitter Linkedin
    Privacy Policy Disclaimer Terms of Use Sitemap